Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure

INTRODUCTION: Based upon the findings of the African-American Heart Failure Trial, the US Food and Drug Administration approved the fixed-dose combination of isosorbide dinitrate (ISDN) and hydralazine hydrochloride (HYD) (FDC-ISDN/HYD) as a new drug for treatment of heart failure (HF) in self-ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Ofili, Elizabeth, Anand, Inder, Williams, Richard Allen, Akinboboye, Ola, Xu, Liou, Puckrein, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565652/
https://www.ncbi.nlm.nih.gov/pubmed/28707284
http://dx.doi.org/10.1007/s12325-017-0584-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565652/
https://www.ncbi.nlm.nih.gov/pubmed/28707284
http://dx.doi.org/10.1007/s12325-017-0584-x

Ejemplares similares